Lista de obras - Daniele Generali - Dominio Público Uruguay

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial

artículo científico publicado en 2016

A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers

artículo científico publicado en 2016

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

artículo científico publicado en 2014

Advances in systemic therapy for malignant mesothelioma: future perspectives

artículo científico publicado en 2017

Apatinib for the treatment of gastric cancer

artículo científico publicado en 2016

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

artículo científico publicado en 2017

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

artículo científico publicado en 2018

Avelumab in gastric cancer

scientific article published on 06 May 2019

Bevacizumab in small cell lung cancer

artículo científico publicado en 2017

Breast tumour angiogenesis

artículo científico publicado en 2007

Broad targeting of angiogenesis for cancer prevention and therapy

artículo científico publicado en 2015

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines

artículo científico publicado en 2016

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

artículo científico publicado en 2018

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.

artículo científico publicado en 2017

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

artículo científico publicado en 2014

Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120]

article

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

artículo científico publicado en 2017

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

artículo científico publicado en 2018

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

scientific article published on 07 August 2018

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

artículo científico publicado en 2015

Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

artículo científico publicado en 2020

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

artículo científico publicado en 2013

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma

artículo científico publicado en 2017

Enzalutamide in Prostate Cancer after Chemotherapy ⬇️

artículo científico publicado el 20 de diciembre de 2012

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis

artículo científico publicado en 2016

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

artículo científico publicado en 2015

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations

artículo científico publicado en 2015

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

artículo científico publicado en 2020

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials

artículo científico publicado en 2016

Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis

artículo científico publicado en 2017

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

artículo científico

Is it time for everolimus-based combination in castration-resistant prostate cancer?

artículo científico publicado en 2016

Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.

artículo científico publicado en 2017

Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?

artículo científico publicado en 2017

Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis

artículo científico publicado en 2018

Isolated Testicular Metastasis from Prostate Cancer.

artículo científico publicado en 2017

Lenvatinib for the treatment of renal cell carcinoma.

artículo científico publicado en 2018

Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.

artículo científico

Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer

artículo científico publicado en 2016

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience

scientific article published on 17 July 2018

Mutant p53 as an Antigen in Cancer Immunotherapy

artículo científico publicado en 2020

Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient

artículo científico publicado en 2016

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

artículo científico publicado en 2016

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When

artículo científico publicado en 2019

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

artículo científico publicado en 2016

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

artículo científico publicado en 2014

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue

scientific article published on 01 April 2019

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy

artículo científico publicado en 2017

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer

artículo científico publicado en 2018

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

artículo científico publicado en 2011

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

artículo científico publicado en 2015

Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press

artículo científico publicado en 2016

Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate C

artículo científico publicado en 2016

Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies

artículo científico publicado en 2017

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.

artículo científico publicado en 2017

Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.

artículo científico publicado en 2016

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

artículo científico publicado en 2016

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

artículo científico publicado en 2011

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial ⬇️

artículo científico publicado el 11 de abril de 2011

Targeting bone metastatic cancer: Role of the mTOR pathway

artículo científico

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials

artículo científico publicado en 2016

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments ⬇️

artículo científico publicado en 2020

The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis

scientific article published on 22 August 2013

The Treatment of Individual Patients Is More Than a Trial ⬇️

artículo científico publicado el 1 de enero de 2011

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis

artículo científico publicado en 2018

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

artículo científico publicado en 2011

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

artículo científico publicado en 2017

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

scientific article published in 2022

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

artículo científico publicado en 2017

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

artículo científico publicado en 2019

Lista de obras de Daniele Generali

A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial

A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

Advances in systemic therapy for malignant mesothelioma: future perspectives

Apatinib for the treatment of gastric cancer

Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Avelumab in gastric cancer

Bevacizumab in small cell lung cancer

Breast tumour angiogenesis

Broad targeting of angiogenesis for cancer prevention and therapy

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120]

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma

Enzalutamide in Prostate Cancer after Chemotherapy ⬇️

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials

Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Is it time for everolimus-based combination in castration-resistant prostate cancer?

Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.

Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?

Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis

Isolated Testicular Metastasis from Prostate Cancer.

Lenvatinib for the treatment of renal cell carcinoma.

Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.

Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience

Mutant p53 as an Antigen in Cancer Immunotherapy

Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press

Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate C

Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.

Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial ⬇️

Targeting bone metastatic cancer: Role of the mTOR pathway

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments ⬇️

The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis

The Treatment of Individual Patients Is More Than a Trial ⬇️

The prognostic value of PI3K mutational status in breast cancer: a meta-analysis

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.